de Mendoza Carmen, Cabezas Teresa, Caballero Estrella, Requena Silvia, Amengual María J, Peñaranda María, Sáez Ana, Tellez Raquel, Lozano Ana B, Treviño Ana, Ramos José M, Pérez José L, Barreiro Pablo, Soriano Vicente
aPuerta de Hierro Research Institute, Madrid bHospital de Poniente, Almeria cHospital Vall d'Hebrón, Barcelona dCorporación Sanitaria Parc Taulí, Sabadell eSon Espases Hospital, Palma de Mallorca fHospital Marqués de Valdecilla, Santander gFundación Jiménez Díaz, Madrid hGeneral Hospital, Alicante iLa Paz University Hospital & Autonomous University, Madrid, Spain.
AIDS. 2017 Jun 19;31(10):1353-1364. doi: 10.1097/QAD.0000000000001485.
: HIV type 2 (HIV-2) is a neglected virus despite estimates of 1-2 million people infected worldwide. HIV-2 is less efficiently transmitted than HIV-1 by sex and from mother to child. Although AIDS may develop in HIV-2 carriers, it takes longer than in HIV-1-infected patients. In contrast with HIV-1 infection, there is no global pandemic caused by HIV-2, as the virus is largely confined to West Africa. In a less extent and due to socioeconomic ties and wars, HIV-2 is prevalent in Portugal and its former colonies in Brazil, India, Mozambique and Angola. Globally, HIV-2 infections are steadily declining over time. A total of 338 cases of HIV-2 infection had been reported at the Spanish HIV-2 registry until December 2016, of whom 63% were men. Overall 72% were sub-Saharan Africans, whereas 16% were native Spaniards. Dual HIV-1 and HIV-2 coinfection was found in 9% of patients. Heterosexual contact was the most likely route of HIV-2 acquisition in more than 90% of cases. Roughly one-third presented with CD4 cell counts less than 200 cells/μl and/or AIDS clinical events. Plasma HIV-2 RNA was undetectable at baseline in 40% of patients. To date, one-third of HIV-2 carriers have received antiretroviral therapy, using integrase inhibitors 32 individuals. New diagnoses of HIV-2 in Spain have remained stable since 2010 with an average of 15 cases yearly. Illegal immigration from Northwestern African borders accounts for over 75% of new HIV-2 diagnoses. Given the relatively large community of West Africans already living in Spain and the continuous flux of immigration from endemic regions, HIV-2 infection either alone or as coinfection with HIV-1 should be excluded once in all HIV-seroreactive persons, especially when showing atypical HIV serological profiles, immunovirological disconnect (CD4 cell count loss despite undetectable HIV-1 viremia) and/or high epidemiological risks (birth in or sex partners from endemic regions).
尽管据估计全球有100万至200万人感染了2型人类免疫缺陷病毒(HIV-2),但它仍是一种被忽视的病毒。与HIV-1相比,HIV-2通过性传播以及母婴传播的效率较低。虽然HIV-2携带者可能会发展为艾滋病,但这比HIV-1感染患者所需的时间更长。与HIV-1感染不同,HIV-2并未引发全球大流行,因为该病毒主要局限于西非地区。在较小程度上,由于社会经济联系和战争,HIV-2在葡萄牙及其在巴西、印度、莫桑比克和安哥拉的前殖民地较为流行。在全球范围内,HIV-2感染人数随着时间的推移在稳步下降。截至2016年12月,西班牙HIV-2登记处共报告了338例HIV-2感染病例,其中63%为男性。总体而言,72%为撒哈拉以南非洲人,而16%为西班牙本地人。9%的患者被发现同时感染了HIV-1和HIV-2。在90%以上的病例中,异性接触是感染HIV-2最可能的途径。大约三分之一的患者CD4细胞计数低于200个/微升和/或出现艾滋病临床症状。40%的患者在基线时血浆HIV-2 RNA检测不到。迄今为止,三分之一的HIV-2携带者接受了抗逆转录病毒治疗,其中32人使用了整合酶抑制剂。自2010年以来,西班牙HIV-2的新诊断病例数一直保持稳定,平均每年15例。来自西北非洲边境的非法移民占新HIV-2诊断病例的75%以上。鉴于已经有相当数量的西非社区居民生活在西班牙,以及来自流行地区的移民持续涌入,对于所有HIV血清反应阳性者,尤其是那些表现出非典型HIV血清学特征、免疫病毒学脱节(尽管HIV-1病毒血症检测不到但CD4细胞计数下降)和/或高流行病学风险(在流行地区出生或性伴侣来自流行地区)的人,都应排除单独感染HIV-2或同时感染HIV-1和HIV-2的情况。